We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PGC:NASDAQPeapack-Gladstone Financial Corporation Analysis

Data as of 2026-05-19 - not real-time

$42.34

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Peapack‑Gladstone Financial (PGC) posted a spectacular earnings beat, with net income jumping 86% YoY and revenue climbing 25.5% YoY, driving EPS to $2.47 and pushing forward EPS expectations to $4.77. The stock now trades at $42.34, comfortably above its 20‑day SMA (41.63) and 50‑day SMA (38.17) but still below the 200‑day SMA (31.11), indicating a bullish medium‑term trend despite a bearish MACD histogram. Valuation metrics are compelling: the DCF model values the shares at $114.38, implying a 14% upside, while the forward P/E of 8.9 and a modest price‑to‑book of 1.12 suggest the market is pricing in only a fraction of the intrinsic value. Dividend sustainability looks strong, with a low payout ratio of 8% and a cash balance of $264 M against $114 M of debt, supporting the 0.47% yield.
Technical signals are mixed – RSI sits at 61, indicating mild overbought pressure, volume is trending down, and the MACD signal is bearish – but the overall bullish trend direction and strong earnings momentum outweigh short‑term softness. Investors should weigh the undervalued pricing, robust growth outlook, and solid capital position against modest liquidity concerns and sector regulatory headwinds.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish SMA alignment with price above 20‑day SMA
  • Strong earnings beat and revenue growth
  • Bearish MACD histogram and decreasing volume suggesting short‑term caution

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF fair value indicating ~14% upside
  • Forward P/E of 8.9 versus industry average
  • Sustainable dividend with low payout ratio

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Consistent earnings momentum and target ROA/RoC improvements
  • Undervalued relative to intrinsic valuation and peer P/E
  • Strong balance sheet with ample cash and modest debt

Key Metrics & Analysis

Financial Health

Revenue Growth25.50%
Profit Margin16.02%
P/E Ratio17.1
ROE6.64%
ROA0.59%
P/B Ratio1.1
Op. Cash Flow$75.6M
Industry P/E16.7

Technical Analysis

TrendBullish
RSI61.0
Support$38.82
Resistance$43.83
MA 20$41.63
MA 50$38.17
MA 200$31.11
MACDBearish
VolumeDecreasing
Fear & Greed Index89.34

Valuation

Fair Value$114.38
Target Price$48.44
Upside/Downside14.40%
GradeUndervalued
TypeBlend
Dividend Yield0.47%

Risk Assessment

Beta1.01
Volatility30.14%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.